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THE ROLE OF CYTOTOXIC T CELL ANTIGEN-2 (CTLA2) IN MOUSE
HEMATOPOIETIC STEM CELL (HSC) TRANSPLANT ENGRAFTMENT AND
RECONSTITUTION EXAMINED BY LENTIVIRAL VECTOR TRANSDUC-
TION
Yankelevich, M.1, Volonakis, E.2, Goodell, M.A.2 1. Baylor College of
Medicine/ Texas Children’s Cancer Center, Houston, TX; 2. Baylor
College of Medicine/ Center for Cell and Gene Therapy, Houston, TX.
HSCs are rare cells resident in the bone marrow. HSCs must be
capable of robust proliferation and self-renewal. The regulation of
HSC proliferation occurs at least partly through interactions with
the microenvironment, or niche. We found that in contrast to
other bone marrow cells, HSCs constitutively express high levels of
CTLA2, and that after treatment with 5-FU, CTLA2 is down-
regulated in HSCs. We hypothesize that interaction between ca-
thepsin L and the endogenous cathepsin L inhibitor CTLA2 reg-
ulates interaction of HSCs with the quiescent niche. In this study,
bone marrow cells from 5-FU treated mice were transduced with
lentiviral vectors encoding ﬁve different transgenes (CTLA2
 and
 expression constructs, siRNA CTLA2
 and 
/ knockdown
constructs, and empty construct) and were transplanted into le-
thally irradiated mice with unmanipulated competitors. The short-
term, long-term, and lineage engraftment of transduced HSCs was
studied. Peripheral blood analysis at 4 weeks after transplant dem-
onstrated that 90 to 100% of the animals transplanted with empty
and CTLA2 knockdown constructs engrafted as oppose to 0 to
25% of the mice transplanted with CTLA2 expression transgenes.
The mean percentage of peripheral blood leukocytes derived from
the lentivirally transduced cells at 4 weeks post-transplant was 17%
for empty construct, 19% for CTLA2
/ knokdown construct,
6% for CTLA2
 knockdown construct, 1.5% for CTLA2
 ex-
pression construct, and 0% for CTLA2 expression construct. The
differences between empty and knockdown versus expression con-
structs were statistically signiﬁcant. When the analysis was re-
peated at 8 weeks post-transplant, the same result was observed.
Next, we did lineage distribution analysis of engrafted populations
at 	12 weeks post-transplant. We did not ﬁnd signiﬁcant differ-
ence between the distribution of granulocytes, T cells, and B cells
within peripheral blood leukocytes derived from engrafted popu-
lations when compared to untransduced cells. Thus, our prelimi-
nary ﬁndings demonstrated that HSCs transduced with CTLA2
over expression lentiviral constructs have inferior ability to engraft
(or may be impaired multilineage reconstitution?) compared to
empty and CTLA2 knockdown constructs. In the future, we plan
to study biological responses of modiﬁed HSCs to cytotoxic and
mobilization stimuli in vivo.
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EXPANSION OF UMBILICAL CORD BLOOD DERIVED OLIGODENDRO-
CYTES
Beam, D.T.1, Thacker, J., Kurtzberg, J.1 Duke University Medical
Center, Durham, NC.
Transplantation of children with lysosomal storage diseases
(LSD) with unrelated donor-umbilical cord blood (UCB) is effec-
tive in preventing onset and progression of severe neurologic
symptoms if performed early in the course of the disease. Unfor-
tunately, many children are not diagnosed before moderate to
severe neurologic damage has occurred. These symptomatic chil-
dren experience disease stabilization after transplant but do not
regain lost function. This may be due to the fact that irreversible
damage has occurred or, conversely, that stem cells transit to the
brain too slowly to effect neural cell repair. To address this prob-
lem, we have developed in vitro methods to isolate and characterize
oligodendrocytes derived from human UCB. We previously de-
scribed these methods and the initial characterization of these cells
(Hall et al). Continuing to advance this work, we now are focusing
on further characterization and expansion of this population of
cells in preparation for a phase I human clinical trial in patients
with symptomatic LSD. Human UCB is red cell depleted with
hetastarch, mononuclear cells are isolated with ﬁcol density sepa-
ration, and plated at a density of 5  105 cells/ml in media
containing neurotropin 3, vascular endothelial growth factor, and
platelet derived growth factor. The adherent cells are washed 2
per week for 2 weeks, then passaged and replated at a density of 5
103 cells/ml with media changes twice weekly, once with the
original oligodendrocyte media and the second with NeuroCult
media (StemCell Technologies, Vancouver). Cells expand with an
approximate doubling time of 6.5 days. After 4 and 6 week periods,
a 16- and 64-fold expansion can be seen, respectively. We antici-
pate that using a 20% fraction (200 106 cells) of a cord blood unit
we can obtain 33  108 cells in 6 weeks. Oligodendrocyte lineage
identity of these cells, post expansion, was conﬁrmed by PCR based
methods with expression of myelin basic protein, nestin, PLP, and
Neurogenin 3. We conclude that oligodendrocytes can be isolated
and expanded from human UCB yielding sufﬁcient numbers of
cells for testing in phase I human trials to facilitate neural cell
repair in patients with advanced LSD.
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OPTIMUM TEMPERATURE FOR MAINTAINING THE VIABILITY OF
CD34 CELLS DURING STORAGE AND TRANSPORT OF FRESH HAEMA-
TOPOIETIC PROGENITOR CELLS
Antonenas, V.1, Garvin, F.1, Sartor, M.1, Bradstock, K.1, Gottlieb, D.1
Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney,
NSW, Australia.
The optimum conditions for storage and transport of freshly
harvested hemopoietic progenitor cells (HPC) in the liquid state is
uncertain. It is not speciﬁed in commonly applied standards for
stem cell transplantation. We used a viable CD34 assay to deter-
mine the optimum temperature for maintaining progenitor cell
viability in freshly harvested bone marrow and peripheral blood
stem cells. Our aim was to identify standardized conditions for
storage and transport of marrow or peripheral blood products that
would optimize CD34 recovery leading to better transplant out-
comes. Samples were aseptically removed from 46 fresh HPC
harvests (34 PBSC and 12 BM) and stored at refrigerated temper-
ature (2°–8° C), room temperature (18°–24° C) and 37° C, for up
to 72 hours. Samples were analysed for viable CD34 cells/ml at
0, 24, 48, and 72 hours.
The mean viable CD34 yield prior to storage was 7.7 106/Kg
(range 0.7–30.3). The mean loss of viable CD34 cells in HPC
products at refrigerated temperature was 9.4%, 19.4%, and 28% at
24, 48, and 72 hours, respectively. In contrast, the mean loss of
viable CD34 cells at room temperature was 21.9%, 30.7%, and
43.3% at 24, 48, and 72 hours, respectively. No viable CD34
cells remained after storage at 37° C for 24 hours. Only PBSC
products and not BM showed temperature related loss of CD34
viability. Greater loss of viable CD34 cells was observed for
allogeneic PBSC compared to autologous PBSC. These results
demonstrate that the optimum temperature to maintain the viabil-
ity of CD34 cells during overnight storage and transport of
freshly harvested HPC is 2°–8° C. These ﬁndings allow for the
development of standard guidelines for HPC storage and trans-
port.
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DIFFUSE ALVEOLAR HEMORRHAGE (DAH) AND INFECTION ASSOCI-
ATED ALVEOLAR HEMORRHAGE (IAH) FOLLOWING HEMATOPOIETIC
STEM-CELL TRANSPLANTATION: RELATED AND HIGH RISK CLINICAL
SYNDROMES WITH POOR RESPONSE TO HIGH-DOSE CORTICOSTE-
ROIDS
Majhail, N.S.1, Parks, K.A.1, Defor, T.E.1, Weisdorf, D.J.1 Blood and
Marrow Transplant Program, University of Minnesota, Minneapolis,
MN.
Diffuse alveolar hemorrhage (DAH) is a non-infectious pul-
monary complication of hematopoietic stem-cell transplanta-
tion (HSCT) and is associated with signiﬁcant mortality. The
pathogenesis and treatment of DAH is unclear. We reviewed
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prospectively collected data on 1958 consecutive HSCTs per-
formed between 1995 and 2004 and compared patients with
DAH and infection associated alveolar hemorrhage (IAH) who
presented with similar hypoxemia, pulmonary inﬁltrates, and
progressively bloody alveolar lavage but also had microorgan-
isms (excluding Aspergillus spp) isolated from blood, bronchoal-
veolar lavage (BAL), or tracheal aspirate within 1 week of
alveolar hemorrhage. Overall, 116 (5.9%) patients had alveolar
hemorrhage diagnosed by BAL (DAH  45, IAH  71). Sixty-
day mortality from the onset of alveolar hemorrhage was 74%
(95% conﬁdence-interval (CI), 66–82%). For the whole cohort,
presence of infection (P  .04) and hemorrhage within 5 days of
engraftment (P  .01) were predictive of survival beyond 60
days from onset of alveolar hemorrhage. The DAH and IAH
groups were comparable except for greater use of total body
irradiation containing conditioning regimen in the DAH group
(P  .04) and umbilical cord blood donor source in the IAH
group (P  .04). Survival at 60 days from the onset of alveolar
hemorrhage was 16% (95% CI, 5–27%) for the DAH group and
32% (95% CI, 21%–43%) for the IAH group (P  .18). All
except 20 patients (DAH  4, IAH  16) were treated with a
standard regimen of high-dose corticosteroids. The steroid and
no-steroid groups were comparable except for a trend towards
greater use of corticosteroids in the DAH group (P  .06). Sixty
day survival from the onset of alveolar hemorrhage was 26%
(95% CI, 17–35%) in patients receiving corticosteroids com-
pared to 25% (95% CI, 6–44%) in those not receiving corti-
costeroids (P  .17). The pathogenesis of alveolar hemorrhage
following HSCT is multifactorial and we propose that IAH and
DAH are related clinical syndromes with similar clinical pre-
sentation, risks, and associated high mortality. Furthermore, our
results show no beneﬁt of high-dose corticosteroids in the
management of this disorder. Ongoing study to identify the
pathophysiologic mechanisms of alveolar injury and to deﬁne
new therapy is still needed.
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POSACONAZOLE (POS) VS FLUCONAZOLE (FLU) FOR PROPHYLAXIS OF
INVASIVE FUNGAL INFECTIONS (IFIs) IN ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS WITH GRAFT-VER-
SUS-HOST DISEASE (GVHD): A MULTICENTER TRIAL
Durrant, S.1, Vesole, D.2, Langston, A.3, Lipton, J.H.4, Patino, H.5,
Pedicone, L.5, Ullmann, A.J.6 1. Royal Brisbane Hospital, Brisbane,
Australia; 2. Medical College of Wisconsin, Milwaukee, WI; 3. Emory
University Hospital, Atlanta, GA; 4. Princess Margaret Hospital, To-
ronto, ON, Canada; 5. Schering-Plough Research Institute, Kenilworth,
NJ; 6. Johannes Gutenberg University, Mainz, Germany.
Introduction: Allogeneic HSCT recipients are at risk for life-
threatening IFI. In patients with GVHD, IFIs are mainly due to
moulds, limiting the utility of prophylactic FLU. We compared
POS with FLU in preventing IFI in HSCT recipients with GVHD
on intensive immunosuppressives. Methods: Patients in this dou-
ble-blind, double-dummy study received oral POS (200 mg tid) or
FLU (400 mg qd) for up to 16 weeks (112 days). Incidence of IFI
was determined at 16 weeks and up to 7 days after last dose by
EORTC/MSG criteria adjudicated by a blinded expert panel. Re-
sults: 600 patients were enrolled (301 POS; 299 FLU). Mean
duration of therapy was 80 days in the POS arm and 77 days in the
FLU arm. Incidence of proven/probable IFIs is shown below.
Mortality rate due to IFI was POS (1%) versus FLU (4%); overall
rate was 25% versus 28%. Safety and tolerability were comparable.
Discontinuations due to treatment failure were lower for POS
versus FLU (3% vs 8%); those due to adverse events were similar
(33% each).Conclusions: POS was superior to FLU in preventing
aspergillosis and other breakthrough IFIs in HSCT recipients with
GVHD. Although POS was noninferior to FLU in preventing
total IFIs during the study period, the criteria for superiority were
not met. This may be because of the high rate of discontinuation
before day 112 (45% of POS patients and 52% of FLU patients),
contributing to the small number of IFI events. Both agents were
well tolerated (Table1).
Table 1.
Proven/Probable IFIs
POS,
n (%)
FLU,
n (%)
Odds Ratio
(95% CI)
P
Value
IFIs during study period (day 112)
Total 16 (5) 27 (9) 0.56 (0.30–1.1) .07
Aspergillus 7 (2) 21 (7) 0.31 (0.13–0.75) .006
Breakthrough infections (while on treatment)
Total 7 (2) 22 (8) 0.30 (0.12–0.71) .004
Aspergillus 3 (1) 17 (6) 0.17 (0.05–0.57) .001
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ACTIVE TREATMENT OF ASYMPTOMATIC RADIOLOGICALLY DOCU-
MENTED SINUSITIS MAY BE NECESSARY FOR PATIENTS RECEIVING
TOTAL BODY IRRADIATION CONDITIONING
Kwon, J.M.1, Jung, C.W.1, Kim, W.S.1, Kim, K.M.1, Chung, S.K.1,
Kang, W.K.1, Park, K.1 Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea.
Background: In hematopoietic stem cell transplantation
(HSCT), careful evaluation of paranasal sinus is necessary be-
cause increased risk of sinusitis may be problematic during
post-transplant neutropenic period. However, there are no cri-
teria for diagnosis and optimal treatment of asymptomatic ra-
diologically documented or symptomatic sinusitis. Methods: A
retrospective review of the medical records of 256 patients who
received autologous (n  124) or allogeneic (n  128) HSCT
for hematologic malignancies at Samsung Medical Center from
April 1996 to December 2003 was performed. Four patients
were excluded because of tumor originated in nasal cavity.
Radiologically documented sinusitis was deﬁned as mucosal
thickening, opaciﬁcation and air-ﬂuid level of sinus without
symptom. Symptomatic sinusitis was deﬁned as symptoms such
as postnasal drip, rhinorrhea, nasal obstruction, cough, fever,
headache with radiologic abnormalities.
Results: The median age was 38 years (range 15–68 years). One
hundred thirty-three (52.8%) of 252 patients had no evidence of
sinusitis and 23 (9.1%) patients had symptomatic sinusitis before
transplantation. The remaining 96 patients (38.1%) had asymp-
tomatic radiologically documented sinusitis. All symptomatic si-
nusitis were treated sufﬁciently before proceeding to HSCT. Of 96
patients with radiologically documented sinusitis, but without
symptom, 54 were treated with antibiotics, 6 were operated endo-
scopically, and 36 were not treated.
After transplantation, sinusitis developed in 76 patients (30.2%), 40
(15.9%) were documented clinically and 36 (14.3%) were radiologi-
cally. Median day of onset of sinusitis was 52.5 days (range 1–420
days) after transplantation. There were no deaths or graft failure
related to sinus complications. In patients with asymptomatic radio-
logically documented sinusitis, there was no difference in the inci-
dence of post-transplant sinusitis among surgery and medical therapy
and observation (P  .479). In patients who received total body
irradiation (TBI) as conditioning regimen, radiologically documented
sinusitis was related to higher risk of developing post-transplantation
sinusitis (P  .033). Conclusions: Our data suggest that aggressive
treatment of asymptomatic radiologically documented sinusitis at pre-
transplantation may not be necessary. However, if recipient is sched-
uled to receive of TBI as conditioning regimen, active treatment of
asymptomatic radiologically documented sinusitis is to be considered.
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ACUTE GRAFT-VERSUS-HOST DISEASE AND IMMUNOSUPPRESSIVE
THERAPY IDENTIFY PATIENTS LESS LIKELY TO HAVE A DIAGNOSTIC
YIELD WITH A BRONCHOALVEOLAR LAVAGE: THE ST. JUDE EXPERI-
ENCE 1990–2002
Kasow, K.A.1, King, E.2, Rochester, R.J.1, Tong, X.1, Srivastava, D.K.1,
Horwitz, E.M.1, Leung, W.1, Woodard, P.1, Handgretinger, R.1,
Hale, G.A.1 1. St. Jude Children’s Reseach Hospital, Memphis, TN; 2.
Chicago College of Osteopathic Medicine, Downers Grove, IL.
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